Medical Developments International Limited · ASX:MVP
Medical Developments International — FY2026 Earnings Presentation
18 slides from Medical Developments International's earnings presentation, Aug 20, 2026
Slide 1: FY26 Full Year Results
ASX:MVP FY26 FULL YEAR RESULTS 20 August 2026 1
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation contains summary information about Medical Developments International Limited (ACN 108340667) and its related bodies corporate (together, MVP) and MVP’s activities as at the date of this presentation. It is information given in summary form only and
Slide 3: Important notice and disclaimer
Important notice and disclaimer Factors that could cause actual results to differ materially include: • the success of research and development activities (including clinical trials); • decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label
Slide 4: Key messages
Key messages Solid financial performance, Penthrox® volume growth, Penthrox® addressable market expanded Solid financial performance with strong cashflow generation 1 Group revenue of $42.6m (+9%1); EBIT of $0.2m profit; Free cashflow of $4.2m improved by $5.8m; improved earnings in Pain Management
Slide 5: FY26 Full Year Results
FY26 Full Year Results Revenue Pain Management revenue Respiratory revenue $42.6m $31.6m $10.9m +9% +21% -15% EBIT NPAT Free cashflow $0.2m $0.6m $4.2m +$0.3m +$0.5m +$5.8m 5
Slide 6: FY26 Strategy milestones achieved
FY26 Strategy milestones achieved Penthrox® paediatric indication in Europe broadens the addressable market and strengthens the platform for future growth FY26 priorities Key milestones achieved • Paediatric label approved and launched in UK and Europe • MAGPIE paediatric study published in Injury,
Slide 7: Priorities for FY27
Priorities for FY27 Unlock value from the paediatric indication and accelerate Penthrox® expansion into high-growth markets and segments 1 2 3 2 Accelerate Grow Penthrox® in Enhance margins and penetration of new markets and deliver operational Penthrox segments efficiencies • Unlock value from the
Slide 8: Grow Penthrox in new markets and segments
Grow Penthrox in new markets and segments ® Leverage experience in existing markets to accelerate growth globally Growth Themes • Common adoption rationale for hospitals globally with workflow benefits addressing Emergency Department efficiency Hospital Adoption • Leverage learnings and experience,
Slide 9: Results
RESULTS 9
Slide 10: Results summary
Results summary Penthrox® growth, improved margins and financial discipline $million FY25 FY26 Change $m Commentary Revenue 39.1 42.6 3.5 • Group revenue up 9% EBITDA 3.2 2.9 (0.3) EBIT 0.0 0.2 0.3 • Pain Management revenue up 21% ($5.4m) driven by higher volume, higher average prices NPAT 0.1 0.6 0
Slide 11: Pain Management segment results
Pain Management segment results Revenue up 21%, higher volumes in all regions, higher pricing in Australia $million FY25 FY26 Change % Commentary Europe 8.1 9.0 12% Europe Australia 15.4 17.9 16% • Revenue up 12%, with benefit of higher underlying Rest of World 2.5 4.1 66% demand, and increase in pa
Slide 12: Respiratory segment results
Respiratory segment results Revenue down 15% with soft demand conditions $million FY25 FY26 Change % Commentary Australia 3.4 3.0 (13%) Australia USA 7.3 6.1 (16%) • Seasonally softer demand Europe 1.2 0.6 (52%) Rest of World 0.9 1.2 32% USA Revenue 12.9 10.9 (15%) • Soft demand conditions throughou
Slide 13: EBIT bridge
EBIT bridge Higher Penthrox® volume and pricing EBIT Commentary ($million) Volumes • Stronger underlying Penthrox® growth in all regions 1.1 (1.4) • Lower Respiratory volumes in the US • Timing benefit from increased partner stock holdings Pricing and European transition 1.1 0.7 (2.5) (0.5) • Higher
Slide 14: Cashflow and balance sheet
Cashflow and balance sheet Free cashflow improved $5.8 million, closing cash balance of $21.4m Commentary $million FY25 FY26 Change Operating cash flow • Improved operating cash earnings Operating cash flow (0.0) 5.8 5.8 • $5.2m year on year reduction in working capital utilised because of lower inv
Slide 15: Closing remarks and outlook
Closing remarks and outlook Solid financial performance and progress of Strategy • Solid cashflow generation FY26 • Penthrox® volume growth in all regions • Penthrox® paediatric label approved and launched in UK and European markets • Health economic study completed demonstrating that Penthrox® use
Slide 16: Appendices
APPENDICES 16
Slide 17: Business overview
Business overview The Pain Management segment delivers ~74% of Group revenue, driven by demand for Penthrox® Pain Management Respiratory Supplies pharmacies, medical clinics and hospitals with a range of Description Manufactures Penthrox® , an inhaled, needle-free, non-opioid analgesic respiratory d
Slide 18: Penthrox overview
Penthrox overview ® Efficacy, safety and administration benefits of Penthrox® • Inhaled needle-free analgesic 1 The iconic Green Whistle • Non-opioid1 • Portable, self administered device1 • Effective pain relief within 6–10 breaths1-4 • Established safety profile with over 11 million uses • Well to
Medical Developments International — FY2026 Earnings Presentation on 6ix